Chronic pain is one of the most common complaints affecting modern society with an estimated 25.3 million US adults (11.2%) suffering from this health concern.1 Furthermore, almost 40 million adults (17.6%) have severe levels of chronic pain.1 One of the most severe forms of chronic pain is neuropathic pain, which results from damage to the central or peripheral nervous systems.2 This damage can result from physical trauma such as accidents, surgery, and stroke, diseases such as diabetes, cancer, and immune disorders, and medications such as cancer chemotherapy drugs.2 Neuropathic pain is also often associated with accompanying mental health disorders such as depression, anxiety, sleep problems, and reduced social interactions.
Meletis 2
The scientific evidence is compelling!
The peer-reviewed journal, Alternative Therapies in Health and Medicine, recently published the results of a double-blind study comparing the bioavailability of patented CoQsource Bio-Enhanced CoQ10 to that of other bio-enhanced formulations. The study, entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System,” appears in the March/April, 2009 issue, Volume 15, Number 2.
The graph shows a pharmacokinetic study (single oral dose, crossover) in humans comparing VESIsorb® CoQsource® to the same standard Coenzyme Q10 in different formulation demonstrating an increase of absorption in peak blood levels. The relative bioavialiability of a single oral dose of 120mg of CoQ10 was asserted using the AUC. The results showed 622% higher bioavialiability than the oil-based formula and 499% higher bioavialiability than the solubilizate.
The single oral 120 mg does of the VESIorb® – CoQ10 resulted in a peak plasma level of 6.89 μg/mL compared to 2.24 μg/mL achieved with 120 mg of an oil-based formula.
Analysis of the area under the curve revealed the relative bioavailability of VESIsorb® – CoQ10 was up to 622% compared to the other formulations studied.
